nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

01.09.2011

The ghrelin/GOAT/GHS-R system and energy metabolism

verfasst von: Chung Thong Lim, Blerina Kola, Márta Korbonits

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Ghrelin is a brain-gut peptide that was discovered through reverse pharmacology and was first isolated from extracts of porcine stomach. Ghrelin binds to growth hormone secretagogue receptor (GHS-R) and is acylated on its serine 3 residue by ghrelin O-acyltransferase (GOAT). Several important biological functions of ghrelin have been identified, which include its growth hormone-releasing and appetite-inducing effects. Ghrelin exerts its central orexigenic effect mainly by acting on the hypothalamic arcuate nucleus via the activation of the GHS-R. Peripherally ghrelin has multiple metabolic effects which include promoting gluconeogenesis and fat deposition. These effects together with the increased food intake lead to an overall body weight gain. AMP-activated protein kinase, which is a key enzyme in energy homeostasis, has been shown to mediate the central and peripheral metabolic effects of ghrelin. The hypothalamic fatty acid pathway, hypothalamic mitochondrial respiration and uncoupling protein 2 have all been shown to act as the downstream targets of AMPK in mediating the orexigenic effects of ghrelin. Abnormal levels of ghrelin are associated with several metabolic conditions such as obesity, type 2 diabetes, Prader-Willi syndrome and anorexia nervosa. The ghrelin/GOAT/GHS-R system is now recognised as a potential target for the development of anti-obesity treatment.

Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 2006;89(1):71–84.PubMedCrossRef

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–60.PubMedCrossRef

Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409(6817):194–8.PubMedCrossRef

Soares JB, Roncon-Albuquerque Jr R, Leite-Moreira A. Ghrelin and ghrelin receptor inhibitors: Agents in the treatment of obesity. Expert Opin Ther Targets. 2008;12(9):1177–89.PubMedCrossRef

Momany FA, Bowers CY, Reynolds GA, Chang D, Hong A, Newlander K. Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology. 1981;108(1):31–9.PubMedCrossRef

Leontiou CA, Franchi G, Korbonits M. Ghrelin in neuroendocrine organs and tumours. Pituitary. 2007;10(3):213–25.PubMedCrossRef

Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–7.PubMedCrossRef

Palyha OC, Feighner SD, Tan CP, McKee KK, Hreniuk DL, Gao YD, et al. Ligand activation domain of human orphan growth hormone (GH) secretagogue receptor (GHS-R) conserved from Pufferfish to humans. Mol Endocrinol. 2000;14(1):160–9.PubMedCrossRef

Castaneda TR, Tong J, Datta R, Culler M, Tschop MH. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol. 2010;31(1):44–60.PubMedCrossRef

10.

Chartrel N, Alvear-Perez R, Leprince J, Iturrioz X, Reaux-Le Goazigo A, Audinot V, et al. Comment on “Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake”. Science. 2007;315(5813):766. author reply 766.PubMedCrossRef

11.

Gourcerol G, Coskun T, Craft LS, Mayer JP, Heiman ML, Wang L, et al. Preproghrelin-derived peptide, obestatin, fails to influence food intake in lean or obese rodents. Obes Silver Spring. 2007;15(11):2643–52.CrossRef

12.

Nogueiras R, Pfluger P, Tovar S, Arnold M, Mitchell S, Morris A, et al. Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology. 2007;148(1):21–6.PubMedCrossRef

13.

Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87(6):2988.PubMedCrossRef

14.

Korbonits M, Grossman AB. Ghrelin: Update on a novel hormonal system. Eur J Endocrinol. 2004;151 Suppl 1:S67–70.PubMedCrossRef

15.

Higgins SC, Gueorguiev M, Korbonits M. Ghrelin, the peripheral hunger hormone. Ann Med. 2007;39(2):116–36.PubMedCrossRef

16.

Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem. 2005;280(26):25196–201.PubMedCrossRef

17.

Neary NM, Druce MR, Small CJ, Bloom SR. Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect. Gut. 2006;55(1):135.PubMed

18.

Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell. 2008;132(3):387–96.PubMedCrossRef

19.

Gualillo O, Lago F, Dieguez C. Introducing GOAT: A target for obesity and anti-diabetic drugs? Trends Pharmacol Sci. 2008;29(8):398–401.PubMedCrossRef

20.

Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA. 2008;105(17):6320–5.PubMedCrossRef

21.

Lim CT, Kola B, Igreja SC, Grossman AB, Korbonits M. Expression of ghrelin O-acyltransferase (GOAT), the newly-identified ghrelin acylation enzyme, in various human tissues. Endocr Abstr. 2009;19:P123.

22.

Hofmann K. A superfamily of membrane-bound O-acyltransferases with implications for wnt signaling. Trends Biochem Sci. 2000;25(3):111–2.PubMedCrossRef

23.

Kirchner H, Gutierrez JA, Solenberg PJ, Pfluger PT, Czyzyk TA, Willency JA, et al. GOAT links dietary lipids with the endocrine control of energy balance. Nat Med. 2009;15(7):741–5.PubMedCrossRef

24.

Zhao TJ, Liang G, Li RL, Xie X, Sleeman MW, Murphy AJ, et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci USA. 2010;107(16):7467–72.PubMedCrossRef

25.

Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res. 1997;48(1):23–9.PubMedCrossRef

26.

Schellekens H, Dinan TG, Cryan JF. Lean mean fat reducing “ghrelin” machine: Hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity. Neuropharmacology. 2010;58(1):2–16.PubMedCrossRef

27.

Leung PK, Chow KB, Lau PN, Chu KM, Chan CB, Cheng CH, et al. The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin receptor. Cell Signal. 2007;19(5):1011–22.PubMedCrossRef

28.

Chan CB, Cheng CH. Identification and functional characterization of two alternatively spliced growth hormone secretagogue receptor transcripts from the pituitary of black seabream Acanthopagrus schlegeli. Mol Cell Endocrinol. 2004;214(1–2):81–95.PubMedCrossRef

29.

Leite-Moreira AF, Soares JB. Physiological, pathological and potential therapeutic roles of ghrelin. Drug Discov Today. 2007;12(7–8):276–88.PubMedCrossRef

30.

van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004;25(3):426–57.PubMedCrossRef

31.

Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin-a hormone with multiple functions. Front Neuroendocrinol. 2004;25(1):27–68.PubMedCrossRef

32.

Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol. 2010;44(2):87–97.PubMedCrossRef

33.

Kluge M, Riedl S, Uhr M, Schmidt D, Zhang X, Yassouridis A, et al. Ghrelin affects the hypothalamus-pituitary-thyroid axis in humans by increasing free thyroxine and decreasing TSH in plasma. Eur J Endocrinol. 2010;162(6):1059–65.PubMedCrossRef

34.

Charoenthongtrakul S, Giuliana D, Longo KA, Govek EK, Nolan A, Gagne S, et al. Enhanced gastrointestinal motility with orally active ghrelin receptor agonists. J Pharmacol Exp Ther. 2009;329(3):1178–86.PubMedCrossRef

35.

Carlini VP, Martini AC, Schioth HB, Ruiz RD, Fiol de Cuneo M, de Barioglio SR. Decreased memory for novel object recognition in chronically food-restricted mice is reversed by acute ghrelin administration. Neuroscience. 2008;153(4):929–34.PubMedCrossRef

36.

Kojima M, Hosoda H, Kangawa K. Clinical endocrinology and metabolism. Ghrelin, a novel growth-hormone-releasing and appetite-stimulating peptide from stomach. Best Pract Res Clin Endocrinol Metab. 2004;18(4):517–30.PubMedCrossRef

37.

Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407(6806):908–13.PubMedCrossRef

38.

Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50(8):1714–9.PubMedCrossRef

39.

Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab. 2004;287(2):E297–304.PubMedCrossRef

40.

Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes. 2001;50(11):2438–43.PubMedCrossRef

41.

Small CJ, Bloom SR. Gut hormones and the control of appetite. Trends Endocrinol Metab. 2004;15(6):259–63.PubMedCrossRef

42.

Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86(12):5992.PubMedCrossRef

43.

Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg. 2003;138(4):389–96.PubMedCrossRef

44.

Venkova K, Greenwood-Van Meerveld B. Application of ghrelin to gastrointestinal diseases. Curr Opin Investig Drugs. 2008;9(10):1103–7.PubMed

45.

Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003;37(4):649–61.PubMedCrossRef

46.

Mano-Otagiri A, Nemoto T, Sekino A, Yamauchi N, Shuto Y, Sugihara H, et al. Growth hormone-releasing hormone (GHRH) neurons in the arcuate nucleus (Arc) of the hypothalamus are decreased in transgenic rats whose expression of ghrelin receptor is attenuated: Evidence that ghrelin receptor is involved in the up-regulation of GHRH expression in the arc. Endocrinology. 2006;147(9):4093–103.PubMedCrossRef

47.

Olszewski PK, Grace MK, Billington CJ, Levine AS. Hypothalamic paraventricular injections of ghrelin: Effect on feeding and c-Fos immunoreactivity. Peptides. 2003;24(6):919–23.PubMedCrossRef

48.

Kohno D, Gao HZ, Muroya S, Kikuyama S, Yada T. Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes. 2003;52(4):948–56.PubMedCrossRef

49.

Andrews ZB, Liu ZW, Walllingford N, Erion DM, Borok E, Friedman JM, et al. UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals. Nature. 2008;454(7206):846–51.PubMedCrossRef

50.

Chen HY, Trumbauer ME, Chen AS, Weingarth DT, Adams JR, Frazier EG, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology. 2004;145(6):2607–12.PubMedCrossRef

51.

Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Shimbara T, et al. Ghrelin-induced food intake is mediated via the orexin pathway. Endocrinology. 2003;144(4):1506–12.PubMedCrossRef

52.

Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, Amin F, et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE. 2008;3(3):e1797.PubMedCrossRef

53.

Kageyama H, Takenoya F, Shiba K, Shioda S. Neuronal circuits involving ghrelin in the hypothalamus-mediated regulation of feeding. Neuropeptides. 2010;44(2):133–8.PubMedCrossRef

54.

Hori Y, Kageyama H, Guan JL, Kohno D, Yada T, Takenoya F, et al. Synaptic interaction between ghrelin- and ghrelin-containing neurons in the rat hypothalamus. Regul Pept. 2008;145(1–3):122–7.PubMedCrossRef

55.

Cowley MA. Hypothalamic melanocortin neurons integrate signals of energy state. Eur J Pharmacol. 2003;480(1–3):3–11.PubMedCrossRef

56.

Guan JL, Okuda H, Takenoya F, Kintaka Y, Yagi M, Wang L, et al. Synaptic relationships between proopiomelanocortin- and ghrelin-containing neurons in the rat arcuate nucleus. Regul Pept. 2008;145(1–3):128–32.PubMedCrossRef

57.

Horvath TL, Diano S, van den Pol AN. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: A novel circuit implicated in metabolic and endocrine regulations. J Neurosci. 1999;19(3):1072–87.PubMed

58.

Shrestha YB, Wickwire K, Giraudo SQ. Role of AgRP on Ghrelin-induced feeding in the hypothalamic paraventricular nucleus. Regul Pept. 2006;133(1–3):68–73.PubMedCrossRef

59.

Tschop M, Statnick MA, Suter TM, Heiman ML. GH-releasing peptide-2 increases fat mass in mice lacking NPY: Indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002;143(2):558–68.PubMedCrossRef

60.

Qian S, Chen H, Weingarth D, Trumbauer ME, Novi DE, Guan X, et al. Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol. 2002;22(14):5027–35.PubMedCrossRef

61.

Luquet S, Perez FA, Hnasko TS, Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science. 2005;310(5748):683–5.PubMedCrossRef

62.

Gropp E, Shanabrough M, Borok E, Xu AW, Janoschek R, Buch T, et al. Agouti-related peptide-expressing neurons are mandatory for feeding. Nat Neurosci. 2005;8(10):1289–91.PubMedCrossRef

63.

Ste Marie L, Luquet S, Cole TB, Palmiter RD. Modulation of neuropeptide Y expression in adult mice does not affect feeding. Proc Natl Acad Sci USA. 2005;102(51):18632–7.PubMedCrossRef

64.

Bewick GA, Gardiner JV, Dhillo WS, Kent AS, White NE, Webster Z, et al. Post-embryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype. FASEB J. 2005;19(12):1680–2.PubMed

65.

Tolle V, Low MJ. In vivo evidence for inverse agonism of Agouti-related peptide in the central nervous system of proopiomelanocortin-deficient mice. Diabetes. 2008;57(1):86–94.PubMedCrossRef

66.

Shaw AM, Irani BG, Moore MC, Haskell-Luevano C, Millard WJ. Ghrelin-induced food intake and growth hormone secretion are altered in melanocortin 3 and 4 receptor knockout mice. Peptides. 2005;26(10):1720–7.PubMedCrossRef

67.

Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428(6982):569–74.PubMedCrossRef

68.

Kola B, Boscaro M, Rutter GA, Grossman AB, Korbonits M. Expanding role of AMPK in endocrinology. Trends Endocrinol Metab. 2006;17(5):205–15.PubMedCrossRef

69.

Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005;2(1):9–19.PubMedCrossRef

70.

Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR, et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005;2(1):21–33.PubMedCrossRef

71.

Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Ogura T, Lavin MF, et al. IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem Biophys Res Commun. 2004;324(3):986–92.PubMedCrossRef

72.

Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem. 2006;281(35):25336–43.PubMedCrossRef

73.

Fu X, Wan S, Lyu YL, Liu LF, Qi H. Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS ONE. 2008;3(4):e2009.PubMedCrossRef

74.

Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J. 2007;403(1):139–48.PubMedCrossRef

75.

Qi J, Gong J, Zhao T, Zhao J, Lam P, Ye J, et al. Downregulation of AMP-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue. EMBO J. 2008;27(11):1537–48.PubMedCrossRef

76.

Costanzo-Garvey DL, Pfluger PT, Dougherty MK, Stock JL, Boehm M, Chaika O, et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab. 2009;10(5):366–78.PubMedCrossRef

77.

Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 2007;6(1):55–68.PubMedCrossRef

78.

Kola B, Christ-Crain M, Lolli F, Arnaldi G, Giacchetti G, Boscaro M, et al. Changes in adenosine 5′-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing’s syndrome. J Clin Endocrinol Metab. 2008;93(12):4969–73.PubMedCrossRef

79.

Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: A novel mechanism in Cushing’s syndrome. FASEB J. 2008;22(6):1672–83.PubMedCrossRef

80.

Kola B, Korbonits M. Shedding light on the intricate puzzle of ghrelin’s effects on appetite regulation. J Endocrinol. 2009;202(2):191–8.PubMedCrossRef

81.

Lopez M, Lage R, Saha AK, Perez-Tilve D, Vazquez MJ, Varela L, et al. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 2008;7(5):389–99.PubMedCrossRef

82.

Kohno D, Sone H, Minokoshi Y, Yada T. Ghrelin raises [Ca2+]i via AMPK in hypothalamic arcuate nucleus NPY neurons. Biochem Biophys Res Commun. 2008;366(2):388–92.PubMedCrossRef

83.

Anderson KA, Ribar TJ, Lin F, Noeldner PK, Green MF, Muehlbauer MJ, et al. Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab. 2008;7(5):377–88.PubMedCrossRef

84.

Sleeman MW, Latres E. The CAMplexities of central ghrelin. Cell Metab. 2008;7(5):361–2.PubMedCrossRef

85.

He W, Lam TK, Obici S, Rossetti L. Molecular disruption of hypothalamic nutrient sensing induces obesity. Nat Neurosci. 2006;9(2):227–33.PubMedCrossRef

86.

Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med. 2003;9(6):756–61.PubMedCrossRef

87.

Pocai A, Lam TK, Obici S, Gutierrez-Juarez R, Muse ED, Arduini A, et al. Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J Clin Invest. 2006;116(4):1081–91.PubMedCrossRef

88.

Sangiao-Alvarellos S, Varela L, Vazquez MJ, Boit KD, Saha AK, Cordido F, Dieguez C, Lopez M. Influence of ghrelin and GH deficiency on AMPK and hypothalamic lipid metabolism. J Neuroendocrinol 2010.

89.

Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27(1):73–100.PubMedCrossRef

90.

Kirkham TC, Tucci SA. Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets. 2006;5(3):272–92.PubMedCrossRef

91.

Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410(6830):822–5.PubMedCrossRef

92.

Zbucki RL, Sawicki B, Hryniewicz A, Winnicka MM. Cannabinoids enhance gastric X/A-like cells activity. Folia Histochem Cytobiol. 2008;46(2):219–24.PubMedCrossRef

93.

Rigault C, Le Borgne F, Georges B, Demarquoy J. Ghrelin reduces hepatic mitochondrial fatty acid beta oxidation. J Endocrinol Investig. 2007;30(4):RC4–8.

94.

Sangiao-Alvarellos S, Vazquez MJ, Varela L, Nogueiras R, Saha AK, Cordido F, et al. Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009;150(10):4562–74.PubMedCrossRef

95.

Rodriguez A, Gomez-Ambrosi J, Catalan V, Gil MJ, Becerril S, Sainz N, et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes Lond. 2009;33(5):541–52.PubMedCrossRef

96.

Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, Pfluger P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest. 2006;116(7):1983–93.PubMedCrossRef

97.

Baran K, Preston E, Wilks D, Cooney GJ, Kraegen EW, Sainsbury A. Chronic central melanocortin-4 receptor antagonism and central neuropeptide-Y infusion in rats produce increased adiposity by divergent pathways. Diabetes. 2002;51(1):152–8.PubMedCrossRef

98.

Lage R, Vazquez MJ, Varela L, Saha AK, Vidal-Puig A, Nogueiras R, et al. Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. FASEB J. 2010;24(8):2670–9.PubMedCrossRef

99.

Tsubone T, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Ghrelin regulates adiposity in white adipose tissue and UCP1 mRNA expression in brown adipose tissue in mice. Regul Pept. 2005;130(1–2):97–103.PubMedCrossRef

100.

Barazzoni R, Bosutti A, Stebel M, Cattin MR, Roder E, Visintin L, et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab. 2005;288(1):E228–35.PubMedCrossRef

101.

Sun Y, Asnicar M, Saha PK, Chan L, Smith RG. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 2006;3(5):379–86.PubMedCrossRef

102.

Andrews ZB, Erion DM, Beiler R, Choi CS, Shulman GI, Horvath TL. Uncoupling protein-2 decreases the lipogenic actions of ghrelin. Endocrinology. 2010;151(5):2078–86.PubMedCrossRef

103.

Mano-Otagiri A, Iwasaki-Sekino A, Nemoto T, Ohata H, Shuto Y, Nakabayashi H, et al. Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats. Regul Pept. 2010;160(1–3):81–90.PubMedCrossRef

104.

Krsek M, Rosicka M, Papezova H, Krizova J, Kotrlikova E, Haluz’k M, et al. Plasma ghrelin levels and malnutrition: A comparison of two etiologies. Eat Weight Disord. 2003;8(3):207–11.PubMed

105.

Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med. 2002;8(7):643–4.PubMedCrossRef

106.

Bizzarri C, Rigamonti AE, Luce A, Cappa M, Cella SG, Berini J, et al. Children with Prader-Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children. Eur J Endocrinol. 2010;162(3):499–505.PubMedCrossRef

107.

Goldstone AP, Patterson M, Kalingag N, Ghatei MA, Brynes AE, Bloom SR, et al. Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab. 2005;90(5):2681–90.PubMedCrossRef

108.

Nicholls RD, Knepper JL. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum Genet. 2001;2:153–75.PubMedCrossRef

109.

DelParigi A, Tschop M, Heiman ML, Salbe AD, Vozarova B, Sell SM, et al. High circulating ghrelin: A potential cause for hyperphagia and obesity in prader-willi syndrome. J Clin Endocrinol Metab. 2002;87(12):5461–4.PubMedCrossRef

110.

Gimenez-Palop O, Gimenez-Perez G, Mauricio D, Gonzalez-Clemente JM, Potau N, Berlanga E, et al. A lesser postprandial suppression of plasma ghrelin in Prader-Willi syndrome is associated with low fasting and a blunted postprandial PYY response. Clin Endocrinol Oxf. 2007;66(2):198–204.PubMedCrossRef

111.

Karczewska-Kupczewska M, Straczkowski M, Adamska A, Nikolajuk A, Otziomek E, Gorska M, et al. Increased suppression of serum ghrelin concentration by hyperinsulinemia in women with anorexia nervosa. Eur J Endocrinol. 2010;162(2):235–9.PubMedCrossRef

112.

Liu G, Fortin JP, Beinborn M, Kopin AS. Four missense mutations in the ghrelin receptor result in distinct pharmacological abnormalities. J Pharmacol Exp Ther. 2007;322(3):1036–43.PubMedCrossRef

113.

Ukkola O, Ravussin E, Jacobson P, Snyder EE, Chagnon M, Sjostrom L, et al. Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. J Clin Endocrinol Metab. 2001;86(8):3996–9.PubMedCrossRef

114.

Garcia EA, King P, Sidhu K, Ohgusu H, Walley A, Lecoeur C, et al. The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes. Eur J Endocrinol. 2009;161(2):307–15.PubMedCrossRef

115.

Larsen LH, Gjesing AP, Sorensen TI, Hamid YH, Echwald SM, Toubro S, et al. Mutation analysis of the preproghrelin gene: No association with obesity and type 2 diabetes. Clin Biochem. 2005;38(5):420–4.PubMedCrossRef

116.

Steinle NI, Pollin TI, O’Connell JR, Mitchell BD, Shuldiner AR. Variants in the ghrelin gene are associated with metabolic syndrome in the Old Order Amish. J Clin Endocrinol Metab. 2005;90(12):6672–7.PubMedCrossRef

117.

Bing C, Ambye L, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, et al. Large-scale studies of the Leu72Met polymorphism of the ghrelin gene in relation to the metabolic syndrome and associated quantitative traits. Diabet Med. 2005;22(9):1157–60.PubMedCrossRef

118.

Choi HJ, Cho YM, Moon MK, Choi HH, Shin HD, Jang HC, et al. Polymorphisms in the ghrelin gene are associated with serum high-density lipoprotein cholesterol level and not with type 2 diabetes mellitus in Koreans. J Clin Endocrinol Metab. 2006;91(11):4657–63.PubMedCrossRef

119.

Kuzuya M, Ando F, Iguchi A, Shimokata H. Preproghrelin Leu72Met variant contributes to overweight in middle-aged men of a Japanese large cohort. Int J Obes Lond. 2006;30(11):1609–14.PubMedCrossRef

120.

Kim SY, Jo DS, Hwang PH, Park JH, Park SK, Yi HK, et al. Preproghrelin Leu72Met polymorphism is not associated with type 2 diabetes mellitus. Metabolism. 2006;55(3):366–70.PubMedCrossRef

121.

Korbonits M, Gueorguiev M, O’Grady E, Lecoeur C, Swan DC, Mein CA, et al. A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab. 2002;87(8):4005–8.PubMedCrossRef

122.

Poykko S, Ukkola O, Kauma H, Savolainen MJ, Kesaniemi YA. Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects. Diabetologia. 2003;46(4):455–8.PubMed

123.

Zavarella S, Petrone A, Zampetti S, Gueorguiev M, Spoletini M, Mein CA, et al. A new variation in the promoter region, the −604 C>T, and the Leu72Met polymorphism of the ghrelin gene are associated with protection to insulin resistance. Int J Obes Lond. 2008;32(4):663–8.PubMedCrossRef

124.

Berthold HK, Giannakidou E, Krone W, Mantzoros CS, Gouni-Berthold I. The Leu72Met polymorphism of the ghrelin gene is associated with a decreased risk for type 2 diabetes. Clin Chim Acta. 2009;399(1–2):112–6.PubMedCrossRef

125.

Garcia EA, Heude B, Petry CJ, Gueorguiev M, Hassan-Smith ZK, Spanou A, et al. Ghrelin receptor gene polymorphisms and body size in children and adults. J Clin Endocrinol Metab. 2008;93(10):4158–61.PubMedCrossRef

126.

Gueorguiev M, Lecoeur C, Benzinou M, Mein CA, Meyre D, Vatin V, et al. A genetic study of the ghrelin and growth hormone secretagogue receptor (GHSR) genes and stature. Ann Hum Genet. 2009;73(1):1–9.PubMedCrossRef

127.

Gueorguiev M, Lecoeur C, Meyre D, Benzinou M, Mein CA, Hinney A, et al. Association studies on ghrelin and ghrelin receptor gene polymorphisms with obesity. Obes Silver Spring. 2009;17(4):745–54.CrossRef

128.

Fobi MA. Surgical treatment of obesity: A review. J Natl Med Assoc. 2004;96(1):61–75.PubMed

129.

Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623–30.PubMedCrossRef

130.

Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150(6):2518–25.PubMedCrossRef

131.

Williams DL, Grill HJ, Cummings DE, Kaplan JM. Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology. 2003;144(12):5184–7.PubMedCrossRef

132.

Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, et al. Vaccination against weight gain. Proc Natl Acad Sci USA. 2006;103(35):13226–31.PubMedCrossRef

133.

Perez-Tilve D, Gonzalez-Matias L, Alvarez-Crespo M, Leiras R, Tovar S, Dieguez C, et al. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes. 2007;56(1):143–51.PubMedCrossRef

134.

Ariyasu H, Takaya K, Iwakura H, Hosoda H, Akamizu T, Arai Y, et al. Transgenic mice overexpressing des-acyl ghrelin show small phenotype. Endocrinology. 2005;146(1):355–64.PubMedCrossRef

135.

Iwakura H, Hosoda K, Son C, Fujikura J, Tomita T, Noguchi M, et al. Analysis of rat insulin II promoter-ghrelin transgenic mice and rat glucagon promoter-ghrelin transgenic mice. J Biol Chem. 2005;280(15):15247–56.PubMedCrossRef

Titel: The ghrelin/GOAT/GHS-R system and energy metabolism
verfasst von: Chung Thong Lim
Blerina Kola
Márta Korbonits
Publikationsdatum: 01.09.2011
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 3/2011
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-011-9169-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Central leptin and ghrelin signalling: Comparing and contrasting their mechanisms of action in the brain

Hypothalamic control of energy and glucose metabolism

Obesity-associated insulin resistance in skeletal muscle: Role of lipid accumulation and physical inactivity

Is the GLP-1 system a viable therapeutic target for weight reduction?

Hedonic and incentive signals for body weight control